Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
Catalent came through with the biggest life sciences IPO of what's shaping up to be a record year, pulling in $871.3 million in a blockbuster Wall Street debut.
Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments.
Maryland's ABL has struck a deal to buy a majority stake in Platine Pharma Services, a French contract R&D organization that specializes in substances that provoke an immune response.
Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.
TransCelerate BioPharma, a nonprofit run by 19 of the world's largest drugmakers, formed two years ago to help Big Pharma share resources and stop wasting time and money on noncompetitive work. Now, the group is looking to create a novel platform to standardize how clinical trial sites communicate with sponsors, choosing contractor Cognizant to develop it.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.
Basilea Pharmaceutica ran into an FDA roadblock in its efforts to commercialize a new antibiotic, but the Swiss drug developer already has a green light in Europe, and it's tapping Quintiles' global marketing expertise to launch the treatment on its home continent.
German-headquartered CRO Accovion is expanding its reach in Europe, opening a new shop in Italy and planning to launch a French subsidiary in the fall.
Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.
CRO Theorem Clinical Research has inked a deal with India's Excel Life Sciences to broaden its footprint in the country, expanding its access to clinical trial sites and bolstering its patient-recruitment capabilities.